Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04022616 · ClinicalTrials.gov registry record

Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

A clinical trial of Breast Cancer, sponsored by Ohio State University Comprehensive Cancer Center.

Recruiting
Registry status
99
Enrollment target
1
Study location

NCT04022616: Recruiting study of Breast Cancer, sponsored by Ohio State University Comprehensive Cancer Center.

NCT04022616 is a study of Breast Cancer that is actively recruiting participants, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 99 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04022616, a study of Breast Cancer, is actively recruiting participants, sponsored by Ohio State University Comprehensive Cancer Center.

RECRUITING
Registry status
99 participants
Enrollment target
1
Study location

Study Summary

Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

Conditions Studied

Interventions

  • OTHER Specimen collection

Study Locations (1)

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 99 participants
Start Date 2010-06-04
Est. Completion 2025-12-31

What the Registry Record Tells You About NCT04022616

The ClinicalTrials.gov registry entry for NCT04022616 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Specimen collection is the first listed.

NCT04022616 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT04022616 about?

NCT04022616 is a clinical study titled "Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients". Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

What is the current status of trial NCT04022616?

This trial is currently recruiting. The enrollment target is 99 participants. The study started on 2010-06-04. Estimated completion is 2025-12-31.

What conditions does trial NCT04022616 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT04022616?

The interventions under investigation include: Specimen collection (OTHER).

Who is sponsoring clinical trial NCT04022616?

This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04022616 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.